Clinical Trials | September 05, 2025
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
The medicine was well tolerated, with no unexpected safety issue
The medicine was well tolerated, with no unexpected safety issue
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Subscribe To Our Newsletter & Stay Updated
